Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is demonstrating promising results in early human trials . Ongoing research suggests https://kbookmarking.com/story21347614/retatrutide-emerging-research-and-possible-medical-applications